• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

糖尿病性黄斑水肿的新型药物治疗方法。

Emerging pharmacotherapies for diabetic macular edema.

作者信息

Javey Golnaz, Schwartz Stephen G, Flynn Harry W

机构信息

Department of Ophthalmology, Baylor College of Medicine, 7200-B Cambridge Street, Houston, TX 77030, USA.

出版信息

Exp Diabetes Res. 2012;2012:548732. doi: 10.1155/2012/548732. Epub 2012 Feb 26.

DOI:10.1155/2012/548732
PMID:22474425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3299388/
Abstract

Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus. Although photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME continue to lose vision despite treatment. Pharmacotherapies for DME include locally and systemically administered agents. We review several agents that have been studied for the treatment of DME.

摘要

糖尿病性黄斑水肿（DME）仍然是糖尿病患者视力丧失的一个重要原因。尽管在大型随机临床试验（RCT）中，光凝治疗和对全身代谢因素的强化控制已被报道可取得更好的治疗效果，但一些DME患者尽管接受了治疗仍继续丧失视力。DME的药物治疗包括局部和全身给药的药物。我们综述了几种已被研究用于治疗DME的药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a6a/3299388/2e2d5769b040/EDR2012-548732.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a6a/3299388/019c9e83225c/EDR2012-548732.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a6a/3299388/2e2d5769b040/EDR2012-548732.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a6a/3299388/019c9e83225c/EDR2012-548732.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a6a/3299388/2e2d5769b040/EDR2012-548732.002.jpg

相似文献

1
Emerging pharmacotherapies for diabetic macular edema.糖尿病性黄斑水肿的新型药物治疗方法。
Exp Diabetes Res. 2012;2012:548732. doi: 10.1155/2012/548732. Epub 2012 Feb 26.
2
Emerging pharmacotherapies for diabetic macular edema.
Expert Opin Emerg Drugs. 2007 Nov;12(4):591-603. doi: 10.1517/14728214.12.4.591.
3
Intravitreal steroids for macular edema in diabetes.玻璃体内注射类固醇治疗糖尿病性黄斑水肿
Cochrane Database Syst Rev. 2008 Jan 23(1):CD005656. doi: 10.1002/14651858.CD005656.pub2.
4
Current intravitreal pharmacologic therapies for diabetic macular edema.目前用于治疗糖尿病性黄斑水肿的玻璃体内药物疗法。
Postgrad Med. 2015 Aug;127(6):640-53. doi: 10.1080/00325481.2015.1052523. Epub 2015 Jun 3.
5
Corticosteroid use for diabetic macular edema: old fad or new trend?皮质类固醇治疗糖尿病性黄斑水肿：旧时尚还是新趋势？
Curr Diab Rep. 2012 Aug;12(4):364-75. doi: 10.1007/s11892-012-0281-8.
6
Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study.现实世界中视力较好的糖尿病性黄斑水肿的观察和治疗结果：OBTAIN 研究。
Acta Diabetol. 2019 Jul;56(7):777-784. doi: 10.1007/s00592-019-01310-z. Epub 2019 Mar 22.
7
New Insights in Resistant Diabetic Macular Edema.糖尿病性黄斑水肿耐药性的新见解
Ophthalmologica. 2021;244(6):485-494. doi: 10.1159/000516614. Epub 2021 May 21.
8
Updates on the Clinical Trials in Diabetic Macular Edema.糖尿病性黄斑水肿临床试验的最新进展。
Middle East Afr J Ophthalmol. 2016 Jan-Mar;23(1):3-12. doi: 10.4103/0974-9233.172293.
9
Intravitreal Ranibizumab in Diabetic Macular Edema: Long-Term Outcomes.玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿：长期疗效
Dev Ophthalmol. 2017;60:63-70. doi: 10.1159/000460496. Epub 2017 Apr 20.
10
Diabetic macular edema.糖尿病性黄斑水肿
Dev Ophthalmol. 2014;54:164-73. doi: 10.1159/000360463. Epub 2014 Aug 26.

引用本文的文献

1
Pascal short-pulse plus subthreshold endpoint management laser therapy for diabetic macular edema: the "sandwich technique".帕斯卡短脉冲加阈下终点管理激光疗法治疗糖尿病性黄斑水肿：“三明治技术”
Int J Retina Vitreous. 2022 Jun 2;8(1):32. doi: 10.1186/s40942-022-00381-5.
2
Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema.雷珠单抗与阿柏西普治疗希腊糖尿病性黄斑水肿致视力损害患者的成本效益分析
Cost Eff Resour Alloc. 2016 Apr 14;14:7. doi: 10.1186/s12962-016-0056-1. eCollection 2016.
3
Integration of data from omic studies with the literature-based discovery towards identification of novel treatments for neovascularization in diabetic retinopathy.

本文引用的文献

1
Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.糖尿病视网膜病变临床研究网络治疗方案的基本原理：中心性糖尿病黄斑水肿。
Ophthalmology. 2011 Dec;118(12):e5-14. doi: 10.1016/j.ophtha.2011.09.058.
2
Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.眼内血管内皮生长因子拮抗剂治疗后眼内炎：大学转诊中心六年经验。 （请注意，原文中“vascular [corrected] endothelial growth factor antagonists”中的“vascular”应改为“vascular endothelial”。）
Retina. 2011 Apr;31(4):662-8. doi: 10.1097/IAE.0b013e31821067c4.
3
将组学研究数据与基于文献的发现相结合，以鉴定糖尿病视网膜病变新生血管形成的新治疗方法。
Biomed Res Int. 2013;2013:848952. doi: 10.1155/2013/848952. Epub 2013 Nov 24.
4
Intravitreal Corticosteroids in the Management of Diabetic Macular Edema.玻璃体内注射皮质类固醇治疗糖尿病性黄斑水肿
Curr Ophthalmol Rep. 2013 Sep;1(3). doi: 10.1007/s40135-013-0015-3.
5
Hypoxic retinal Muller cells promote vascular permeability by HIF-1-dependent up-regulation of angiopoietin-like 4.低氧视网膜 Muller 细胞通过 HIF-1 依赖性上调血管生成素样蛋白 4 促进血管通透性。
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3425-34. doi: 10.1073/pnas.1217091110. Epub 2013 Aug 19.
6
Photocoagulation of human retinal pigment epithelial cells in vitro: evaluation of necrosis, apoptosis, cell migration, cell proliferation and expression of tissue repairing and cytoprotective genes.体外人视网膜色素上皮细胞的光凝：坏死、细胞凋亡、细胞迁移、细胞增殖以及组织修复和细胞保护基因表达的评估。
PLoS One. 2013 Aug 1;8(8):e70465. doi: 10.1371/journal.pone.0070465. Print 2013.
7
Blood flow parameters of the central retinal and internal carotid arteries in asymmetric diabetic retinopathy.非对称性糖尿病视网膜病变中视网膜中央动脉和颈内动脉的血流参数
J Ophthalmic Vis Res. 2012 Oct;7(4):295-9.
Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of people with type 1 diabetes.
10 年糖尿病视网膜病变和黄斑水肿的发生率。1 型糖尿病患者样本中的风险因素。
Diabetes Res Clin Pract. 2011 Oct;94(1):126-32. doi: 10.1016/j.diabres.2011.07.004. Epub 2011 Jul 30.
4
The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.DA VINCI 研究：抗 VEGF 陷阱眼在糖尿病黄斑水肿患者中的 2 期主要结果。
Ophthalmology. 2011 Sep;118(9):1819-26. doi: 10.1016/j.ophtha.2011.02.018. Epub 2011 May 5.
5
A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.一项为期 2 年的多中心、随机、双盲、2 期试验，评估聚乙二醇化人血管内皮生长因子抑制剂（贝伐单抗）治疗糖尿病性黄斑水肿的疗效。
Ophthalmology. 2011 Jun;118(6):1107-18. doi: 10.1016/j.ophtha.2011.02.045. Epub 2011 May 6.
6
Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.地塞米松玻璃体内植入物治疗玻璃体切割术后糖尿病性黄斑水肿。
Retina. 2011 May;31(5):915-23. doi: 10.1097/IAE.0b013e318206d18c.
7
Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.氟轻松玻璃体内植入剂长效缓释治疗糖尿病性黄斑水肿的长期疗效。
Ophthalmology. 2011 Apr;118(4):626-635.e2. doi: 10.1016/j.ophtha.2010.12.028.
8
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.RESTORE 研究：雷珠单抗单药治疗或联合激光治疗与单纯激光治疗糖尿病黄斑水肿的比较。
Ophthalmology. 2011 Apr;118(4):615-25. doi: 10.1016/j.ophtha.2011.01.031.
9
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.瑞尼珠单抗联合即刻或延迟激光或曲安奈德联合即刻激光治疗糖尿病黄斑水肿的 2 年扩展随访。
Ophthalmology. 2011 Apr;118(4):609-14. doi: 10.1016/j.ophtha.2010.12.033.
10
Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.随机试验评估玻璃体内雷珠单抗或曲安奈德对视神经视网膜光凝治疗糖尿病性黄斑水肿患眼局灶/格栅激光治疗后黄斑水肿的短期疗效。
Retina. 2011 Jun;31(6):1009-27. doi: 10.1097/IAE.0b013e318217d739.